Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

Journal of Neuro-Oncology

Volumn 130, Issue 3, 2016, Pages 543-552

  Han, Seunggu J ^a   Reis, Gerald ^b   Kohanbash, Gary ^a   Shrivastav, Shruti ^a   Magill, Stephen T ^a   Molinaro, Annette M ^a,b   McDermott, Michael W ^a   Theodosopoulos, Philip V ^a   Aghi, Manish K ^a   Berger, Mitchel S ^a   Butowski, Nicholas A ^a   Barani, Igor ^b   Phillips, Joanna J ^a,b   Perry, Arie ^a,b   Okada, Hideho ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B7 H1; Checkpoint; Immunotherapy; Lymphocyte; Macrophage; Meningioma; PD L1

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; MESOTHELIN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MESOTHELIOMA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; AGED; ANALYSIS OF VARIANCE; DIAGNOSTIC IMAGING; FOLLOW UP; GENE EXPRESSION REGULATION; MACROPHAGE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; T LYMPHOCYTE; TISSUE MICROARRAY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD; B7-H1 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84987677852     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2256-0     Document Type: Article

References (27)

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-oncology 16(Suppl 4):iv1–i63. doi:10.1093/neuonc/nou223
2. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122(1):4–23. doi:10.3171/2014.7.JNS131644
3. Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M (2015) Atypical meningoma: current management dilemmas and prospective clinical trials. J Neurooncol 121(1):1–7. doi:10.1007/s11060-014-1620-1
4. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncology 16(6):829–840. doi:10.1093/neuonc/not330
5. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. doi:10.1056/Nejmoa1412082
6. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466
7. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet 384(9948):1109–1117. doi:10.1016/S0140-6736(14)60958-2
8. Domingues PH, Teodosio C, Ortiz J, Sousa P, Otero A, Maillo A, Barcena P, Garcia-Macias MC, Lopes MC, de Oliveira C, Orfao A, Tabernero MD (2012) Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am J Pathol 181(5):1749–1761. doi:10.1016/j.ajpath.2012.07.033
9. Rossi ML, Cruz Sanchez F, Hughes JT, Esiri MM, Coakham HB (1988) Immunocytochemical study of the cellular immune response in meningiomas. J Clin Pathol 41(3):314–319
10. Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, Huttner AJ, Kleinstein SH, Lee JY, Stern JN, Yaari G, Lovato L, Cronk KM, O’Connor KC (2013) The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-oncology 15(11):1479–1490. doi:10.1093/neuonc/not110
11. Baia GS, Caballero OL, Ho JS, Zhao Q, Cohen T, Binder ZA, Salmasi V, Gallia GL, Quinones-Hinojosa A, Olivi A, Brem H, Burger P, Strausberg RL, Simpson AJ, Eberhart CG, Riggins GJ (2013) NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches. Cancer Immunol Res 1(5):296–302. doi:10.1158/2326-6066.CIR-13-0029
12. Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, Agar NY, Rodig SJ, Bradshaw EM, Santagata S (2015) Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6(7):4704–4716
13. Johnson MD, Vito F, O’Connell MJ (2008) Mesothelin expression in the leptomeninges and meningiomas. J Histochem Cytochem 56(6):579–585. doi:10.1369/jhc.2008.950477
14. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5 (1):e1057388. doi:10.1080/2162402X.2015.1057388
15. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-oncology 17(8):1064–1075. doi:10.1093/neuonc/nou307
16. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Holler C, Preusser M (2015) Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66(2):289–299. doi:10.1111/his.12537
17. Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33(1):42–49
18. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, Palmqvist R (2011) Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24(5):671–682. doi:10.1038/modpathol.2010.234
19. Han SJ, Ahn BJ, Waldron JS, Yang I, Fang S, Crane CA, Pieper RO, Parsa AT (2009) Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport 20(18):1597–1602. doi:10.1097/WNR.0b013e32833188f7
20. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84–88. doi:10.1038/nm1517
21. Mathios D, Ruzevick J, Jackson CM, Xu H, Shah S, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, Lim M (2015) PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol 121(2):251–259. doi:10.1007/s11060-014-1637-5
22. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19(12):3165–3175. doi:10.1158/1078-0432.CCR-12-3314
23. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-oncology 12(4):351–365. doi:10.1093/neuonc/nop023
24. Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C (2014) Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29 (4):153–161. doi:10.1089/cbr.2013.1578
25. Moliterno J, Cope WP, Vartanian ED, Reiner AS, Kellen R, Ogilvie SQ, Huse JT, Gutin PH (2015) Survival in patients treated for anaplastic meningioma. J Neurosurg. doi:10.3171/2014.10.JNS14502
26. Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O’Sullivan MG, Bentley RT, Packer RA, Thomovsky SA, Chen AV, Faissler D, Chen W, Hunt MA, Olin MR, Ohlfest JR (2013) Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res 73(10):2987–2997. doi:10.1158/0008-5472.CAN-12-3366
27. Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20(8):2902–2906